2025
NVOS Novo Integrated Sciences Inc
TEL TE Connectivity Ltd
NOTV Inotiv Inc
PLUG Plug Power Inc
WMT WALMART STORES INC
HZNP Horizon Therapeutics PLC
EXPE Expedia Group Inc
BA Boeing Co
Go

Health Care : Life Sciences Tools & Services | Mid Cap Blend

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets a portfolio of various products that serves a global customer base. The segment is focused on specific segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology and food safety. Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Its products address specific niches within the in vitro diagnostics (IVD) test market.

Closing Price: $370.78

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Below Average) Volume: 211,535 10-day average volume: 249,455: 211,535

June 01, 2023
8:02 am ET	Bio-Rad to Present Company Overview at Jefferies Healthcare Conference Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare...(BusinessWire)
May 08, 2023
8:00 am ET	Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's management will participate in a fireside chat event during the 2023 RBC Capital Markets...(BusinessWire)
May 05, 2023
12:37 pm ET	Bio-Rad's stock leads the S&P 500 decliners, as they suffer the biggest selloff in 36 years after disappointing results. Shares of Bio-Rad Laboratories Inc. (BIO) tumbled 17.5% toward their worst day in 36 years, after the maker of products for the life science research and clinical diagnostics markets reported first-quarter results that missed expectations, amid...(MarketWatch)
6:35 am ET	Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.(Zacks)
May 04, 2023
4:15 pm ET	Bio-Rad Reports First-Quarter 2023 Financial Results Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023. (BusinessWire)
April 27, 2023
9:41 am ET	Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.(Zacks)
April 18, 2023
11:02 am ET	What's in Store for Thermo Fisher (TMO) in Q1 Earnings? Thermo Fisher (TMO) is likely to have generated growth in the first quarter, driven by a favorable business mix and new launches.(Zacks)
April 12, 2023
4:11 pm ET	Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of the market...(BusinessWire)
March 15, 2023
7:58 am ET	Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer Resolve Biosciences, a company pioneering Molecular Cartography(TM) technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and